SE0402832D0 - Methods - Google Patents

Methods

Info

Publication number
SE0402832D0
SE0402832D0 SE0402832A SE0402832A SE0402832D0 SE 0402832 D0 SE0402832 D0 SE 0402832D0 SE 0402832 A SE0402832 A SE 0402832A SE 0402832 A SE0402832 A SE 0402832A SE 0402832 D0 SE0402832 D0 SE 0402832D0
Authority
SE
Sweden
Prior art keywords
encoding
human
copd
relates
enac
Prior art date
Application number
SE0402832A
Other languages
English (en)
Inventor
Simon Smith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0402832A priority Critical patent/SE0402832D0/sv
Publication of SE0402832D0 publication Critical patent/SE0402832D0/sv
Priority to US11/719,607 priority patent/US20090149428A1/en
Priority to EP05803692A priority patent/EP1824994A1/en
Priority to PCT/SE2005/001726 priority patent/WO2006054945A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SE0402832A 2004-11-18 2004-11-18 Methods SE0402832D0 (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE0402832A SE0402832D0 (sv) 2004-11-18 2004-11-18 Methods
US11/719,607 US20090149428A1 (en) 2004-11-18 2005-11-16 Methods for Assessing the Predisposition or Susceptibility to COPD
EP05803692A EP1824994A1 (en) 2004-11-18 2005-11-16 Methods for assessing the predisposition or susceptibility to copd
PCT/SE2005/001726 WO2006054945A1 (en) 2004-11-18 2005-11-16 Methods for assessing the predisposition or susceptibility to copd

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0402832A SE0402832D0 (sv) 2004-11-18 2004-11-18 Methods

Publications (1)

Publication Number Publication Date
SE0402832D0 true SE0402832D0 (sv) 2004-11-18

Family

ID=33516492

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0402832A SE0402832D0 (sv) 2004-11-18 2004-11-18 Methods

Country Status (4)

Country Link
US (1) US20090149428A1 (sv)
EP (1) EP1824994A1 (sv)
SE (1) SE0402832D0 (sv)
WO (1) WO2006054945A1 (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
KR101668813B1 (ko) * 2014-11-04 2016-10-24 강원대학교병원 만성 폐쇄성 폐 질환 진단용 조성물, 키트, 마이크로어레이, 및 이를 이용한 만성 폐쇄성 폐 질환의 진단 방법
CN113957141A (zh) * 2021-12-01 2022-01-21 长沙艾迪康医学检验实验室有限公司 检测与高血压相关基因scnn1b突变的寡核苷酸和其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589726B1 (en) * 1991-09-04 2003-07-08 Metrigen, Inc. Method and apparatus for in situ synthesis on a solid support
US5693756A (en) * 1994-02-28 1997-12-02 The Johns Hopkins University Amiloride-sensitive sodium channel and method of identifying substances which stimulate or block salty taste perception
CA2283293A1 (en) * 1997-03-11 1998-09-17 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
US20030204075A9 (en) * 1999-08-09 2003-10-30 The Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US20020128203A1 (en) * 2000-09-20 2002-09-12 Laurent Schild Methods of identifying inhibitory compounds and uses thereof
AU2002210761A1 (en) * 2000-11-03 2002-05-15 Glaxo Group Limited Method of determining susceptibility to diseases
US6586416B2 (en) * 2001-04-19 2003-07-01 James K. Bubien Methods of treatment using an epithelial sodium channel blocker and an inhibitor of the mineralocorticoid receptor
WO2002087306A2 (en) * 2001-05-01 2002-11-07 Senomyx, Inc. High throughput cell-based assay for monitoring sodium channel activity and discovery of salty taste modulating compounds
US6561775B1 (en) * 2001-05-21 2003-05-13 Wood Group Esp, Inc. In situ separable electric submersible pump assembly with latch device
JP2004528151A (ja) * 2001-06-11 2004-09-16 グラクソ　グループ　リミテッド 薬剤ディスペンサ
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
AU2003291097A1 (en) * 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors

Also Published As

Publication number Publication date
US20090149428A1 (en) 2009-06-11
WO2006054945A1 (en) 2006-05-26
EP1824994A1 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
TW200636075A (en) Detection of nucleic acid variation by cleavage-amplification method
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
MXPA05005945A (es) Evento asr-368 de agrostis y composiciones y metodos para deteccion del mismo.
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
EP2101772A4 (en) NEUROMUSCULAR BLOCKAGE AGENTS WITH INTERMEDIATE DURATION AND THEIR ANTAGONISTS
TW200611911A (en) Antibodies to erythropoietin receptor and uses thereof
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
DK1951633T3 (da) Sammensætning til højstyrke glas, højstyrke glasfibre og artikler deraf
MY153198A (en) Inhibitors of protein aggregation
DE602006017365D1 (de) Zusammensetzungen für die identifizierung von adenoviren
EP1934377A4 (en) METHOD AND COMPOSITIONS FOR IDENTIFYING BIOMARKERS SUITED TO THE DIAGNOSIS AND / OR TREATMENT OF BIOLOGICAL CONDITIONS
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
NO20083153L (no) Kjemiske forbindelser
WO2005083127A3 (en) Genetic polymorphisms associated with stroke, methods of detection and uses thereof
HK1145342A1 (en) Prognosis prediction for melanoma cancer
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
WO2006132739A3 (en) Novel chemical compounds
BRPI0606370A2 (pt) tratamento dos distúrbios de hcv
MX2009004382A (es) Variaciones geneticas asociadas con tumores.
WO2008118415A3 (en) Genetic polymorphisms associated with coronary events and drug response
HK1112928A1 (en) Cspcna isoform modifications and uses thereof
SE0402832D0 (sv) Methods
WO2010042685A3 (en) Inhibitors of the atb(0,+) transporter and uses thereof